Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes cited in the NCCN Clinical Practice Guidelines in Oncology and those recommended by the American Society of Clinical Oncology (ASCO).
The newly updated panel now covers 63 genes linked to more than 11 types of cancer. These additions are intended to provide clinicians with comprehensive information, focusing on genes that have a strong association with cancer risk and clear clinical relevance.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Healthcare professionals can access the expanded test outcomes through a variety of channels, including traditional paper forms, the patient portal of Myriad, and electronic medical record systems such as OncoEMR and EPIC.
According to Myriad, the test detects hereditary cancer syndromes connected to a heightened risk for secondary cancers.
These insights are expected to directly inform treatment strategies aimed at reducing the likelihood of subsequent cancers.
The company noted that national clinical guidelines recommend germline testing for patients diagnosed with breast, ovarian, prostate, colon, and pancreatic cancers.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWhile genomic testing has historically been advised for all individuals with metastatic or advanced cancers, ASCO now also recommends multigene germline testing for individuals who qualify, irrespective of their tumour genomic results.
The test claims to be the sole germline core panel that screens for 100% genes strongly endorsed by ASCO guidelines.
In contrast to many available panels commercially, it does not evaluate genes not included in national recommendations, which may reduce uncertainty related to non-actionable findings.
Additionally, the test incorporates ribonucleic acid (RNA) testing in conjunction with the company’s Variant Classification Program to support variant interpretation using a combination of various tools.
Myriad Genetics chief scientific officer Dale Muzzey said: “While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels.
“Medical societies recommend genes for testing when they influence treatment decisions, and those are the genes we prioritise in the MyRisk Test.”
